BiondVax Pharmaceuticals : Corporate Presentation – March 2020

The Universal

Flu Vaccine

Multi-Season

Multi-Strain

Flu Vaccine

CORPORATE PRESENTATION

MARCH2020

2

SAFE HARBOR STATEMENT

This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction.

All statements in this communication, other than those relating to historical facts, are "forward-looking statements" within the meaning of the United States Private Litigation Reform Act of 1995. You can identify forward-looking statements by terms including ''anticipates,'' ''believes,'' ''could,'' ''estimates,'' ''expects,'' ''intends,'' ''may,'' ''plans,'' ''potential,'' ''predicts,'' ''projects,'' ''should,'' ''will,'' ''would,'' and similar expressions intended to identify forward- looking statements. These forward-looking statements relate to our business and financial performance and condition, as well as our plans, strategies, objectives and expectations for our business, operations and financial performance and condition. However, these forward-looking statements are not guarantees of future performance and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, among others: the risk that drug development involves a lengthy and expensive process with uncertain outcome; BiondVax's ability to successfully develop and commercialize its vaccine; the length, progress and results of any clinical trials; the introduction of competing products; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals to commercialize BiondVax's products; the difficulty in evaluating business prospects; the adequacy of available cash resource and the ability to raise capital when needed; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; changes in the global pharmaceutical industry; changes in customers' budgeting priorities; European Medicines Agency and other regulatory authority approvals; natural disasters; labor disputes; rising interest rates; general market, political or economic conditions in the countries in which we operate; pension and health insurance liabilities; volatility or crises In the financial market; arbitration, litigation and regulatory proceedings; and war or acts of terror.

Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC. Readers are urged to carefully review and consider the various disclosures made in the Company's SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects. These forward-looking statements speak only as of the date of this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as required by law.

One • For All : The Universal Flu Vaccine

3

BIONDVAX ON THE RADAR

More News: http://www.biondvax.com/press-releases/in-the-news/

One • For All : The Universal Flu Vaccine

4

A SEASONAL PROBLEM… A PANDEMIC THREAT

The Flu: A Serious Public Health Challenge

SEASONAL FLU -DESPITEANNUAL VACCINE PRODUCTION (500MILLION DOSES1)

Flu cases:	Severe illness:	Deaths:
up to 20%2
3 - 5 million3	650,0003
or 1.5 billion

• At-riskSeniors: 89% of deaths & most hospitalizations4
• High economic burden: Over $361B in the USA4
• USA: Up to 80,000 deaths and 900,000 hospitalizations5

PANDEMIC FLU

• New pandemic strain: When?… Where?... Which?
• Higher morbidity & mortality worldwide
• Estimated cost in US $413B to $3.79T4

1WHO: http://www.who.int/influenza_vaccines_plan/objectives/objective2/en/ and https://en.wikipedia.org/wiki/Influenza_vaccine#Uptake; 2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596521/;

3WHO: http://www.who.int/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year (varies annually); 4White House Council of Economic Advisors (CEA), Mitigating the Impact of Pandemic Influenza through Vaccine Innovation, September 2019.; 5CDC: www.cdc.gov/flu/about/disease/burden.htm and https://www.nytimes.com/2018/10/01/health/flu- deaths-vaccine.html

5

CURRENT VACCINE FALLS SHORT: THE MISMATCH

The Flu Virus: Frequent and Unpredictable Mutations

Why current solutions fall short…

• Past strains selection→Mismatch phenomenon
• Previous season's vaccine will not necessarily protect against next season's flu strains
• 4-6month production lag

Seasonal Flu Vaccine Effectiveness1

Average 40%, Elderly as low as 9%2

2004-05	10%
2005-06	21%
2006-07	52%
2007-08	37%
2008-09	41%
2009-10	56%
2010-11	60%
2011-12	47%
2012-13	49%
2013-14	52%
2014-15	19%	100%
2015-16	48%	Protection
2016-17	40%
2017-18	38%
2018-19	29%

Measles, Rubella, Diphtheria, Tetanus, etc. 95%-99%

1. VE data: CDC, includinghttps://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm [Retrieved 29 October 2019]
2. World Health Organization: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf

6

THE ELDERLY - AT RISK AND IN NEED

• ~80%of seasonal flu related death occurs in elderly1
• Seasonal vaccine effectiveness as low as9%for elderly2
• 80%of older adults have at least one chronic condition3
• Influenza worsens outcomes of chronic illness
• Elderly flu cost in US estimated4at $56Bper year

(hospitalization, mortality, lost earnings)

NIH:"During the period from 1989 to 1997the vaccination rate for elderly persons ≥65 years of age in the US increased from 30 to 67%. Despite this increase in coverage, mortality and hospitalization rates continued to increaserather than decline as would be expected..."

International Journal of Epidemiology5(Vol. 35, Issue 2, P352-353)

1. Vaccine journal: www.sciencedirect.com/science/article/pii/S0264410X15002315, Table 3;2WHO: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf

1. https://www.ncoa.org/healthy-aging/chronic-disease/;4Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25 (2007) 5086-5096;5https://academic.oup.com/ije/article/35/2/352/694736;

7

MEETING MILESTONES & CATALYSTS

Solid Science, Phase 3 Clinical Stage, Strong IP

							Ongoing Pivotal Clinical
Technology developed							Efficacy Phase 3 trial
	TASE June 2007		Nasdaq: BVXV		Commercial
by Prof. Ruth Arnon				(Europe)
Head BiondVax's SAB		Delisted 2018		2015		pilot facility

2005

Mid 90's					2020
		BiondVax			7 Successful Clinical Trials
		operational		•	Two Phase 1/2 & Five Phase 2
				•	Israel, Europe, USA (NIH)	.

• FDA IND / EMA SA

Co-Inventor of	•818 young adult to elderly participants
•M-001 shown to be safe and
	immunogenic in all studies

One • For All : The Universal Flu Vaccine

8

M-001:A COMMON DENOMINATOR OF FLU VIRUSES

)	PucleoNrotein(NP)	AemHgglutinin(HA)
proteinatrixM(M
1

Now in prefilled syringes

Target Common Regions:Nine common flu regions (epitopes) connected to make one recombinant protein (M-001) produced in E.coli

BiondVax's M-001 Key Advantages	Existing vaccines
Universal: Broad coveragetypes A&B	Strain specific
Single formulation enabling	New vaccine every
year-round vaccination	year
Quick, robustyear-round production	Long (4-6 month)
through E.coli fermentation (6-8 weeks)	production cycle
Induces cellular (CMI) andenhances	Limited vaccine
humoral(HAI priming effect) immune
effectiveness
response to flu
Shelf life up to24 months at2-8⁰C	Not applicable, since
(testing is ongoing) and 6 monthsat ~25⁰C	new vaccine every
(room temperature)	season

One • For All : The Universal Flu Vaccine

9

M-001:THE UNIVERSAL FLU VACCINE

M-001's dual mode of action potentially offers multi-season and multi-strain protection

• Flu viruses areintracellularparasites
• Most of theirlifecycle occursinside our cells, thus areout of the reach of antibodies
• Our immune system mainly fights viral infection withcellular immunity via cytokines

Our immune system has 2 arms:

	Cellular (CMI)				Humoral (HAI)
Works insideinfected cells	BiondVax's M-001		Works outsidecells
	T-cell		Dual Mode of Action		B-cell
	Directly		T-cell
		induces		priming
e.g. T-Helper, CD4, CD8	T-Cells		effect	Produce
		enhances
Produce anti-viral			Antibodies
		B-Cell
cytokines such as
		responses
IL-2	IFN-g

Current vaccines mainly induce only flu strain-specific antibodies

One • For All : The Universal Flu Vaccine

10

ADVANCED CLINICAL DEVELOPMENT

M-001: Safe and Immunogenic in Young Adults to Elderly

•Notreatment-related severe adverse events
Group	Day 0	Day 21	Day 42
•Adverse events were mildto moderate
Treatment	M-001	M-001	Seasonal or Pandemic HA
•All adverse events observed were transient
Control	Saline	Saline	vaccine to all participants
•Immunity: Cellular induced, humoral enhanced	Baseline		CMI	HAI
Phase	Trial	Year	Population (age)	Total			Results
Participants
1/2	BVX-002	2009	Younger Adults (18-49)	63
1/2	BVX-003	2010	Older Adults (55-75)	60
2	BVX-004	2011	Younger Adults (18-49)	200	M-001 was well tolerated and a cellular
2	BVX-005	2012	Elderly (65+)	120		(CMI) and humoral (priming effect)
	immune response was observed
2	BVX-006	2015	Older Adults (50-65)	36
2b	BVX-007a	2015-16	EU Adults (18-60)	219
2	BVX-008b	2018	USA Adults (18-49)	120c
				818
3	BVX-010	2018	E. European Adults (50+)	12,463		Results expected by end of 2020

1. BVX-007was conducted in collaboration with the EU's UNISEC consortium.
2. BVX-008conducted and led by NIAID/NIH.
3. Data published January 2020. Clinical study report expected Q2 2020.

11

M-001:INDUCES CELL MEDIATED IMMUNITY (CMI)

Direct Evidence:CD8, CD4 T-cell Activated Cells Produce TH1 Cytokines (IFN-gamma,IL-2 & TNF-alpha)

BVX0051: CD4 & IFN-gamma in Elderly

SE)+

0.3

M-001 twice Day 0

**

0.25

*

*

M-001 twice Day 42

(Mean

0.2

cells

0.15

*

*

0.1

positive%

0

0.05

A/Brisbane/10/07 A/California/7/09

A/Perth/16/09 B/Brisbane/60/08 Flumist 2011

H3N2

H1N1

H3N2

% positive cells (Mean + SE)

BVX0051: CD8 & IFN-gamma in Elderly

0.3

*

M-001 twice Day 0

*

M-001 twice Day 42

0.25

0.2

0.15

0.1

* P<0.05

0.05

**P<0.07

0

A/Brisbane/10/07

A/California/7/09

A/Perth/16/09 B/Brisbane/60/08

Flumist

H3N2

H1N1

H3N2

UNISEC (EU): Statistically significant anti viral cytokines

UNISEC (EU): 13 fold increase in responders expressing 2 cytokines (18-60Y)

	10
placebo																					* P<0.05
8			6.8*
over	6							3.8		5.3*		4.7
change	4
2
Fold
0																		0.4*
																		-0.2
M-001: 1mg 0.5mg		1mg	0.5mg 1mg	0.5mg

placebo	14
12						13.5*
over	10
8													6.6*
change	6																3.5*
Fold	4			2.1*
			1.3
2														0.0
	0

M-001: 1mg 0.5mg 1mg 0.5mg 1mg 0.5mg

"Multiple-Cytokine- Producing Antiviral CD4 T Cells Are Functionally Superior to Single- Cytokine-Producing

Cells"

S Kannanganat et al, J VIROL, 2007, 81(16)8468-76

IFN-gamma

IL-2

TNF-alpha

Single

Double

Triple

1Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population. Vaccine 32 (2014) 5816-5823

12

M-001:ENHANCES HUMORAL IMMUNITY (HAI)

Indirect Evidence:Extending T-Cell Priming Effect for Enhanced HAI Responses to Current Flu Vaccines

BVX0051: 2011/12, age 65+ YO

	70	*
Seroconversion	60							TIV		Twice M-001 + TIV
50
40
30
20

"M-001 can provide broadened enhanced immunity extending even to influenza strains destined to circulate in future years." - Vaccine 2

%	10
	0

A/California/7/09 A/Perth/16/09 B/Brisbane/60/08

H1N1 pandemic swine flu

BVX003: 2009, age 55-75 YO

	80							TIV			Twice M-001 + TIV
seroconversion	70
60
50
40
30
20
%
	10
	0

In 2011 we

administered M-001 to seniors 65+ (BVX005)

4 years later, 5 times moreseniors were seroprotected from a newepidemic strain (A/Swiss) that didn't exist in 2011!

	70
		*
(HAI)	60
50
% Seroprotection	40
30
20
10
	0
	TIV 2011/12	M-001 & TIV 2011/12

A/Brisbane/59/07

A/Brisbane/10/07

B/Brisbane/60/08

* P<0.05

1. Jacob Atsmon et al. Priming by a novel universal influenza vaccine(Multimeric-001)-A gateway for improving immune response in the elderly population. Vaccine 32 (2014) 5816-5823
2. Lowell GH et al. Back to the future: Immunization withM-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain. Vaccine (2017)

13

PIVOTAL CLINICAL EFFICACY PHASE 3 TRIAL (EUROPE)

1. pivotal, multicenter, randomized, modifieddouble-blind,placebo-controlled phase 3 trial to assess the safety and clinical efficacy of M-001, an influenza vaccine, administered intramuscularly

twice in older adults and the elderly (≥50 years of age)

Trial Design:	Cohort 1 (4,042 enrolled & randomized Aug-Oct 2018)
Cohort 2 (8,421 enrolled & randomized July-Nov 2019)
Flexible

enrollment	Day 1	Day 21	Day 202	12,463 participants
Experimental	1mg M-001	1mg M-001	Safety, RT-PCR or	Age 50+ (half 65+)
			culture on any ILI	Two flu seasons
Control	Placebo	Placebo	(during flu season)	Results by end of 2020

• ILI symptoms active surveillancethroughout flu seasons
• Primary endpoints:Safety & clinical efficacy by reduction of illness rate
• Secondary endpoint:Reduced severity of influenza illness

One • For All : The Universal Flu Vaccine

14

BIONDVAX'S NEW MANUFACTURING FACILITY

From Lab to Pilot Mid-Size Commercial Scale Facility

• Funding: EIB, BiondVax, and Israel's Ministry of Economy & Industry
• Target annual capacity: Up to 20 million doses in bulk with up to 10 million single dose syringes
• Goal:Year-round GMP production & stockpile per market demand

Jerusalem BioPark

Hadassah Ein Kerem Campus

Jerusalem, Israel

One • For All : The Universal Flu Vaccine

					15
BIONDVAX:FIRST-IN-CLASS,BEST-IN-CLASS
			Phase
Player	Technology	Pre-	I	II	Status
		clinical	III
BiondVax	M-001: Synthetic protein B- & T-cell peptides (HA, M1,				Statistically significant European Ph2b trial UNISEC
			consortium. NIAID/NIH sponsored ongoing collaboration
	NP). Broad coverage, 6 completed clinical trials in adults	N=13,281
		Phase 2 in USA.
	18 to 65+
				Ongoing pivotal, clinical efficacy Phase 3 trial (Europe).
Imutex +	FLU-V: 4 T-cell peptides adjuvanted formulation				2016: Seek created Imutex with hVIVO
N=408			2020: hVIVO acquired by Open Orphan (AIM: ORPH)
	Challenge and immunogenicity trials
				Phase 2 trials (field, challenge) positive results
	M2SR (RedeeFlu): Single replication virus; Broadening				Phase 2 challenge, intranasal, 2019 interim results
	immunogenicity to flu sub type H3N2.	N=389			'serum antibody response.' Equity funding $27m,
	First in human results reported 2018. Immunogenic in			including $5.5m Aug 2017; $27m gov't grants.
	mice				NIAID sponsored Phase 1, began 2019.
	OXV836: Recombinant poly-Arg NP (H1 strain) in VLP,				Phase 1 results expected H2 2019. Phase 2a results
	N=372			expected 2021. Raised total €11m, including €8m July
	produced in E.coli. CD8 T-cell activation
				2019.
					Phase 1 interim results (2019), elicited cross reactive
	Chimeric H1 targeting stalk of group 1 (H1,H2,H5)	N=108			anti-stalk serum IgG antibodies. NIAID-sponsored Phase
					1 in children.
	H1ssF_3928: H1 HA stem + ferritin nanoparticle.	N=70			Phase 1 began 2019, results expected 2020.
	NIH infrastructure
Academic labs	Stem-only immunogens based on rational design; DNA
	and RNA vaccines. Heterosubtypic protection in mice,				Results in animals.
	ferrets, primates
Based on publicly available information. Last updated February 2020

One • For All : The Universal Flu Vaccine

16

SUMMARY FINANCIAL DATA

• Lean structurewith 20 employees. Manufacturing scale-up

and operating burn ~$410K/month (excluding ongoing Phase 3 clinical trial)

• Fully funded through end of ongoing Phase 3 clinical trial:
• • €24M EIBnon-dilutiveco-funding agreement1
  • Rights offeringJuly 2019, $20M gross proceeds2
  • Secondary offeringSept 2017, $10M gross proceeds
  • Government of Israel supportfrom Ministry of
    Economy and Industry's Israel Investment Center, and royalty-based grants from the Israel Innovation Authority (formerly Office of the Chief Scientist)

American Depository Shares ticker:

BVXV

BVXVW

1European Investment Bank (EIB) €24M support for M-001 Phase 3 trials and commercial production also includes:

• Milestone based drawdowns received in 2018 and 2019
• Zero-percentfixed interest loan for five years after each of the 4 drawdowns
• Variable remuneration based on royalties of net sales

2http://www.biondvax.com/2019/07/biondvax-announces-rights-offering-fully-subscribed-at-us20-million/

17

FLU VACCINES - A LARGE AND GROWING MARKET

Global Flu Vaccine Sales - 2018

Flu Vaccine Market

Seasonal Flu

Others

~$1.3B1

Others

25%

$0.11B92%

Seqirus

21%

$1.09B8

2014/5: CSL bought Novartis' Flu vaccine unit, rebranded to Seqirus

$0.70B6

GSK 13%

Sanofi

39%

$2.01B7

2017: Acquired Protein Sciences for $750M

1. Worldwide: $5.2Bglobal market in 2018; expected to

grow to $7.5Bby 20241

1. USA: $1.6Bin 20152growing to $2.5Bby 20223; ~169M

doses in 2018/1910

1. ForecastedCAGR of 6.37%1

Pandemic Flu

1. Swine Flu (A/H1N1) 2009 + first half of 2010 sales:$5-6Bworldwide by Novartis, GSK and Sanofi (on top of seasonal flu vaccine sales)4

1. >1B pandemic vaccines doses ordered in 200911

"The United States has spent approximately $1 billionin these [H5N1 flu vaccine stockpile] efforts to date."5

"…part of our nation's overall pandemic preparedness strategy…stockpile of bulk vaccine…for influenza viruses with

pandemic potentialto vaccinate 26 million people immediately

after a pandemic is declared."12

1. https://www.researchandmarkets.com/research/5q8dvw/(2)https://www.cnbc.com/2015/10/19/the-16-billion-business-of-flu.html(3)https://www.marketwatch.com/press-release/united-states-influenza-vaccine-market-size-global-industry-analysis-segments-top-key-players-drivers-and-trends-to-2022-2019-02-27(4)www.vaczine-analytics.com/ER_January_100128s.pdf(5)http://www.who.int/immunization/sage/meetings/2013/november/SAGE_WG_H5vaccine_background_paper_16Oct2013_v4.pdf (6)https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2018/#tab-1-3 [At exchange rate 1.33] (7)https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/press-releases/Q42018results.pdf,page 7 [At exchange rate 1.18] (8)YE June 2018 https://www.csl.com/-/media/shared/documents/results/2018-fy-analyst.pdf, page 25 (9)https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report- 2018/PDF/AstraZeneca_AR_2018.pdf, page 69 (10)https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm(11)https://www.theglobeandmail.com/life/health-and-fitness/health/conditions/how-vaccines-became-big-business/article572731/(12)https://www.phe.gov/ASPRBlog/Lists/Posts/Post.aspx?ID=322

18

MANAGEMENT

Ron Babecoff	Tamar	Uri Ben-Or	Elad Mark	Joshua Phillipson
Ben-Yedidia
DVM, MEI	CPA, MBA	BSc Engineering, MBA	Hon. BSc, MBA
PhD
Founder,	CSO & Clinical Trial	CFO	COO	Director of Business
President & CEO	Leader	Development & IR
•DVM (University of Liège)	•Co-inventor of the universal	•BA Business (College of	•BSc. Engineering (Afeka Tel	•Hon. BSc. (University of
•Master in Entrepreneurship &	flu vaccine	Administration)	Aviv College of Engineering)	Toronto)
Innovation (ISEMI, Swinburne)	•PhD (Weizmann Institute of	•MBA (Bar Ilan University)	•MBA (Open University of Israel)	•MBA (Ben Gurion University
•Omrix Biopharmaceuticals Ltd	Science)	•Certified Public Accountant	•Principal bioprocess engineer	of the Negev)
•Biotechnology General Ltd.
(Marketing Manager)	(CPA)	•Novartis (Technical Project	•Accenture (Business
•Dexcel Pharma (Regional		•Glycominds Ltd. (VP	Manager - Process)	Management Consultant)
Export Manager)		Finance)		•BioData Ltd. (Marketing
		•Menorah Capital Markets		Manager)
		(Comptroller)

One • For All : The Universal Flu Vaccine

19

BOARD OF DIRECTORS

Mr. Mark Germain	Aentib Group (Managing Director), Pluristem (Director). Founder, director,
Chairman of the Board	chairman, and/or investor in over twenty biotech companies
Prof. Avner Rotman, PhD	Biodar (CEO), Rodar (Founder), Israel Biotech Organization (Chairman,
Director	Steering committee)
Dr. George Lowell, MD	ID Biomedical (CSO), Intellivax (Founder), Walter Reed General Hospital
Director	(Consultant)
Ron Babecoff, DVM, MEI	Omrix Pharmaceuticals Ltd (Marketing Manager), Dexcel Pharma
Founder, President and CEO	Technologies Ltd. (Formerly Dexxon, Regional Export Manager)
Mr. Isaac Devash, MBA	Credit Suisse First Boston (Investment Banking), Private equity and venture
Director	capital funds (Founder)
Mrs. Michal Marom Brikman, CPA	Linkury Technology International Group (CFO), Union Bank, Spectronix,
Director	Biomedix incubator, ADO group, Arko holdings, Algomizer (Director)
Dr. Ruth Ben Yakar, PhD	BioSight Ltd (CEO, Director), SHL Telemedicine (Director), Cellect
Director	Biotechnology (Director)
Dr. Morris C. Laster, MD	BioLineRx (CEO, Director), OurCrowd (Partner), Clil Medical (CEO), Vital
Director	Spark (CEO), Kitov Pharmaceuticals (Co-founder, Director)

One • For All : The Universal Flu Vaccine

					20
CAP TABLE
	Nasdaq: BVXV	ADS	%	ADS	Expiration
	Nov 2019	Outstanding1	Price	Date
	Ordinary ADS	10,058,791	80.3%
	Options	643,843	5.2%	Variable	Variable
	ADS Warrants	1,819,959	14.5%	$ 6.25	May 15, 2020
	Fully Diluted Shares	12,522,593	100.00%
	Outstanding

1Voluntarily delisted from Tel Aviv Stock Exchange January 22, 2018. (ADS-Shares 1:40 ratio)

One • For All : The Universal Flu Vaccine

21

IP: COMPREHENSIVE AND EXPANDING COVERAGE

• 74 Patents & 11 Pending Applications
• Covering polypeptides, polynucleotides, compositions, uses, formulations, production
• Expiration to 2035

Title	International	Subject Matter	Priority &	Status	Expiry
(updated: March 2020)	Publication	Assignee
Peptide-Based Vaccine for		Vaccine comprising	11/30/1998: Yeda	Granted: USA
WO 00/032228	different epitopes of	R&D licensed to	Expired:1, 3, 5, 12, 13, 15, 19, 20,	USA: Aug 2020
Influenza
	the virus	BiondVax	22, 24, 25, 26, 31, 33, 35, 36
		Wide-range vaccines	12/6/2005: Yeda R&D	Granted:1, 2, 3, 5, 9, 12, 13, 14, 18,	Dec 2026
Improved Influenza Vaccine	WO 2007/066334	- broad strain and
licensed to BiondVax	19, 20, 23, 25, 28, 31, 32, 33, 35, 36	USA: Jan 2027
		extended protection
		Vaccines comprising		Granted:1, 2, 3, 4, 5, 6, 7, 8, 9, 11,	Aug 2028
Multimeric Multi-Epitope Influenza		multiple copies of		12, 13, 15, 16, 17, 18, 19, 20, 21, 22,
WO 2009/016639	8/2/2007: BiondVax	Brazil: Nov 2029
Vaccines	several epitopes -	23, 24, 25, 27, 28, 29, 30, 31, 32, 33,
		USA: Aug 2031
		current product		34, 35, 36
Multimeric Multi-Epitope		Use of Multimeric as			Feb 2031
Polypeptides in improved Seasonal	WO 2012/114323	a primer to	BiondVax	Granted: 1, 5, 36
USA: May 2031
and Pandemic Influenza Vaccines		conventional vaccines
Vaccine Compositions of		Production &		Allowed: 1, 21, 36
Multimeric Multi-epitope Influenza	WO 2015/151103	4/3/2014: BiondVax	April 2035
formulation	Pending: 5, 6, 10, 15, 17, 19
Polypeptides and their Production

1=Australia, 2=Austria, 3=Belgium, 4=Brazil, 5=Canada, 6=China, 7=Croatia, 8=Czech Republic, 9=Denmark, 10=Europe, 11=Finland, 12=France, 13=Germany, 14=Greece, 15=Hong Kong, 16=Hungary, 17=India, 18=Ireland, 19=Israel, 20=Italy, 21=Japan, 22=Korea, 23=Luxembourg, 24=Mexico, 25=Netherlands, 26=New Zealand, 27=Poland, 28=Portugal, 29=Romania, 30=Russia, 31=Spain, 32=Sweden, 33=Switzerland, 34=Turkey, 35=UK, 36=USA.

The Universal

FluVaccine

Multi-Season

Multi-Strain

Flu Vaccine

CONTACT INFORMATION:

JOSHUA PHILLIPSON

[e-mail][phone]

www.biondvax.com